Biomarkers of conversion to α-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder

Mitchell G. Miglis(Stanford Medicine), Wolfgang H. Oertel(Philipps University of Marburg)

The Lancet Neurology

July 21, 2021

10.1016/s1474-4422(21)00176-9

Cited by 239

Related Papers

The natural history of multiple system atrophy: a prospective European cohort study

|The Lancet Neurology|2013|533

Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial

|The Lancet Neurology|2019|125

Neuronally Derived Extracellular Vesicle α-Synuclein as a Serum Biomarker for Individuals at Risk of Developing Parkinson Disease

|JAMA Neurology|2023|114

<scp>Multi‐disciplinary</scp> collaborative consensus guidance statement on the assessment and treatment of autonomic dysfunction in patients with <scp>post‐acute</scp> sequelae of <scp>SARS‐CoV</scp>‐2 infection (<scp>PASC</scp>)

|PM&R|2022|77

Multidisciplinary collaborative guidance on the assessment and treatment of patients with Long <scp>COVID</scp> : A compendium statement

|PM&R|2025|21